Inhibrx ROCE
Cos'è ROCE di Inhibrx?
ROCE di Inhibrx, Inc. è 758.45%
Qual è la definizione di ROCE?
Il ritorno sul capitale investito (ROCE) è un rapporto finanziario che misura la redditività di un'azienda e l'efficienza con cui viene utilizzato il suo capitale.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE di aziende nel Health Care settore su NASDAQ rispetto a Inhibrx
Cosa fa Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Aziende con roce simili a Inhibrx
- Molecular Data Inc ha ROCE di 682.69%
- 9 Meters Biopharma ha ROCE di 684.23%
- Biosig Technologies Inc ha ROCE di 689.29%
- BioCardia ha ROCE di 724.72%
- Elfato ha ROCE di 731.09%
- ContraFect Corp ha ROCE di 754.78%
- Inhibrx ha ROCE di 758.45%
- Corvus Gold ha ROCE di 760.11%
- Havn Life Sciences Inc ha ROCE di 763.04%
- Sabine Royalty Trust ha ROCE di 785.68%
- Winners ha ROCE di 793.33%
- American Environmental ha ROCE di 831.71%
- Killi ha ROCE di 837.33%